CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Early viral kinetics do not predict treatment outcome with sofosbuvir+ribavirin for 12 or 24 weeks in HCV genotype 2/3 patients in the valence trial
DOI 10.1055/s-0034-1386163
Bibliografische Angaben
Nachweis in CareLit
Autor:innenC Eisenbach, S Christensen, N Grüner, R Heyne, H Hinrichsen, D Hüppe, MP Manns, J Petersen, J Schulze-zur-Wiesch, U Spengler, D Häussinger, M Rössle, T Berg, D Brainard, W Symonds, J McHutchison, L Gallo, T Warger, N Forestier, S Zeuzem
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Sofosbuvir (SOF) + ribavirin (RBV) for 12 or 24 weeks led to high SVR rates in genotype 2 or 3 HCV-infected patients, respectively, in the Phase 3 VALENCE study. We analyzed viral kinetics to determine the relationship to SVR12. Methods: Treatment-naïve or treatment-experienced patients infected with HCV genotype 2 or 3 were randomized to receive SOF+RBV for 12 weeks or placebo. The study was amended to…
Zitieren
Zitierempfehlung
C Eisenbach, S Christensen, N Grüner, R Heyne, H Hinrichsen, D Hüppe, MP Manns, J Petersen, J Schulze-zur-Wiesch, U Spengler, D Häussinger, M Rössle, T Berg, D Brainard, W Symonds, J McHutchison, L Gallo, T Warger, N Forestier, S Zeuzem (2014) Early viral kinetics do not predict treatment outcome with sofosbuvir+ribavirin for 12 or 24 weeks in HCV genotype 2/3 patients in the valence trial. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0034-1386163
Mit CareLit weiterarbeiten